ANZCTR search results

IMT has been recognised as a novel form of resistance training in recent years, generating surprising results including improved blood pressure and autonomic balance in patients with hypertension. OSA . and reductions in systemic vascular resistance in healthy young adults. The findings are impressive as each study was able to attain these results within a simple 6-week training program consisting of only 5 min/day for 5 days/week or 25 min/week total training time. There is evidence that IMT performed daily improves casual blood pressure and plasma catecholamines in adults with OSA and elevated or stage 1 hypertension. The effect IMT has on 24-hour blood pressure, a better predictor of blood pressure related end-organ damage, requires further elucidation. A recent study has found reduced systolic blood pressure with high resistance IMT in OSA patients with moderate-to-severe OSA. However, the effect of high and low resistance training on patients with OSA and existing hypertension remains unclear. We hypothesise that high-intensity IMT training will result in lower blood pressure for obstructive sleep apnoea patients with hypertension. We hypothesise that IMT will improve obstructive sleep apnoea severity in patients with hypertension. We hypothesise that IMT will be a well-tolerated device for reducing blood pressure in this group.

This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program, which is registered on ANZCTR with ID ACTRN12616000908437. This substudy will evaluate the activity of Entrectinib advanced cancers harbouring NTRK or ROS1 gene alterations identified using comprehensive genomic profiling. Who is it for? You may be eligible to join the study if you are aged 18 years and older, with pathologically confirmed advanced and/or metastatic solid cancer of any cell type or an earlier diagnosis of a poor prognosis cancer and have received all standard anticancer therapy, or if you have newly diagnosed metastatic non-small cell lung cancer. Your tumour will need to have an NTRK fusion or ROS1 gene alterations. Study details Participants will continue to receive Entrectinib orally at a dose of 600 mg every 28 days continuously as long as they and their doctor agree there is a benefit from treatment. Participants will undergo imaging assessments at 8 weekly intervals for 12 months and then 12 weekly, or as clinically indicated in order to evaluate tumour response. Safety and tolerability of treatment and health related quality of life during treatment will be assessed at 4 weekly intervals. We cannot guarantee that patients will receive any benefits from this study. This study is being carried out to improve the way we treat cancer patients who may have limited treatment options available to them. It is hoped that entrectinib will be well tolerated and will improve outcomes for future patients, however, there may be no clear benefit from participation in this study.

Recovering from a bushfire, drought or COVID-19 can impact individuals emotionally, physically and financially. This study is a randomised controlled trial and aims to help people recover from these impacts by randomly allocating participants to one of two groups: (i) the SOLAR program which is a low intensity psychosocial intervention involving 5 face-to-face or telehealth sessions with a “Coach” who is trained and supervised by Phoenix Australia, OR (ii) an ONLINE program where participants receive weekly emails for 5 weeks with fact sheets and links to resources. Participants will also be asked to complete self-report measures at pre-treatment, post-treatment and follow-up. We hypothesise that the SOLAR program will be more effective then the ONLINE program in reducing the severity of distress at post-treatment and follow-up. The outcomes for this study have the potential to influence large scale roll-out of the SOLAR program in disaster impacted communities.

We hypothesise that people who receive a short treatment encouraging people to set and achieve goals after a diagnosis of mild cognitive impairment or dementia will result in improved quality of life. The ‘Take Charge’ intervention is a short (2 session) therapeutic intervention which encourages people with chronic health conditions to consider their values and what is important to them and how they will maximise their quality of life in the coming months. The ‘Take Charge’ intervention was tested in two randomised controlled trials in New Zealand and was shown to be effective in improving health related quality of life when used with people after stroke. We are proposing to adapt the ‘Take Charge’ intervention with minor modifications and test the intervention with people with mild cognitive impairment and dementia. We are proposing to conduct a pilot study which will test feasibility and inform a larger trial of efficacy. Within the pilot we will be able to determine the feasibility of recruitment to the trial, randomising to the treatment arms, delivering the intervention in this population, and applying the outcome measures. We will also be able to explore whether people who received the intervention found it to be beneficial through both the quantitative data and interviews with people who received the intervention.

Angiotensin II is an endogenous peptide that causes potent vasoconstriction and promotes the release of aldosterone from the zona granulosa of the adrenal gland. The ATHOS-3 study demonstrated that continuous infusion of angiotensin II could effectively augment mean arterial pressure compared to placebo in patients with catecholamine refractory shock. Secondary analyses suggested that angiotensin II may be of particular benefit in patients with acute kidney injury, especially in those with a high ratio of angiotensin I to II. This prospective study will examine the renal outcomes of critically ill patients with distributive shock who receive angiotensin II compared to noradrenaline. Patients who meet all of the inclusion criteria and none of the exclusion criteria will receive a continuous intravenous infusion of angiotensin II until resolution of their distributive shock. The renal outcomes and survival of patients receiving angiotensin II will be compared to those of control patients who received noradrenaline in the preceding period.

The macronutrient fat is almost never consumed on its own but together with other macronutrients. The presence of fat in the digestive tract stimulates the release of the digestive peptide cholecystokinin (CCK) which in turn mediates feelings of fullness, eventually resulting in satiation (meal termination). There is evidence that CCK and stomach distension may work in combination to greater enhance such feedback. The presence of fat and high energy dense carbohydrates in the modern diet may result in a higher than optimal energy intake taking place prior to satiation, leading to weight gain and obesity. The purpose of this study is to determine whether the satiating properties of fat may be more effectively realised by combining fat with low energy dense carbohydrate in the diet.

This study involves the evaluation of an online CBT-based intervention (Reframe IT) delivered to secondary school students in North-West Melbourne. This study forms part of a larger study (the MAPSS project) which also involves delivery of educational workshops to school students. The educational workshops will be evaluated using a pre-test post-test study design. Participants in the current trial will be students who have experienced suicidal ideation in the past four-weeks, identified via their responses to the baseline questionnaire for the MAPSS project. Eligible participants will be invited to participate, and those who consent will be randomised to either Reframe IT or TAU conditions. The intervention period occurs between 2- and 12-weeks post-baseline assessment. The primary outcome is change in suicidal ideation; secondary outcomes are change in depression, hopelessness, and problem-solving skills.

The aim of this project is to investigate whether or not using the right internal mammary artery (rather than the ascending aorta) as a source of blood inflow for coronary artery bypass graft surgery (CABG) results in superior long term graft patency. CABG has been shown to be the most durable method of myocardial revascularisation. Efforts to further extend the long-term benefits of CABG have mainly focussed primarily on improving graft patency rates by using arterial grafts. Less attention has been paid to graft haemodynamics, particularly the source of graft inflow, and the role that this may play in prolonging graft patency. We know that high wall sheer stress leads to graft failure and we believe that gentler mammary artery inflow may encourage improved graft harm-dynamics and therefore patency. We plan to randomise patients undergoing CABG to standard practice (which involves using the ascending aorta as inflow) or to a composite graft group (using the right internal mammary artery as inflow) in order to assess whether or not graft inflow affects patency.

Volunteer hospital staff shall be asked to participate in three phases. The order of the phases shall be randomised. Each shall last for 4 hours. One phase is wearing a standard surgical trilayer mask. Another phase is wearing a fit tested N95 mask, And another is wearing no mask. We shall ask you to complete some baseline questionnaires, a summary of your past medical history, a list of medications, a list of past operations, a psychological assessment tool assessing depression and anxiety, and how short of breath you are feeling. We will also measure your blood pressure, heart rate and oxygen level. Every half an hour, a study investigator will come to you, and using a portable monitor shall measure your oxygen level and ask how short of breath you are feeling, using a scale from 0 to 10 and some simple questions relating dyspnoea to activity,. We shall not show you what your oxygen levels are, a process we call "blinding".

The research project aims to conduct a multicentre trial with 204 caregivers (34 in each of the six study sites) in a 9 month period to evaluate the effectiveness and cost-effectiveness of the Chinese version of WHO iSupport program. The hypotheses tested in the study are described in the following: 1. The generic web-based Chinese iSupport version Carers receiving the iSupport program will report improved quality of life; improved self-efficacy and report improved social support compared to the usual care group at a 6-month follow-up. 2. Compared to those allocated to the usual care group, carers receiving the iSupport program will report reduced dementia related symptoms of the person they care for; report improved quality of life of the person they care for via proxy rating and report fewer unplanned hospital admissions, less emergency department use and less use of permanent residential aged care by the person they care for. 3. The iSupport program will be more cost-effective than the usual care support.